Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Indivior Pharmaceuticals Inc.
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
May 24, 2026
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
May 23, 2026
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
May 22, 2026
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
May 22, 2026
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
May 21, 2026
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
May 19, 2026
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
May 17, 2026
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
May 16, 2026
Indivior Announces Proposed Convertible Senior Notes Offering
May 16, 2026
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
May 16, 2026
1
2
Next Page
→